13737-36-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(Bromomethyl)phenylacetic acid is used as a precursor for the synthesis of serine protease inhibitors, which are important in the development of drugs targeting various diseases, including cancer and inflammatory conditions. Its unique chemical structure allows for the creation of specific inhibitors that can selectively target and regulate the activity of serine proteases.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-(Bromomethyl)phenylacetic acid serves as a key intermediate for the production of various compounds, such as novel crown ether receptors and 4-(acetoxymethyl)phenylacetic acid. By reacting with excessive sodium acetate and acetic acid, it can be further modified to create new molecules with potential applications in different industries.
Used in Research and Development:
4-(Bromomethyl)phenylacetic acid is also utilized in research and development for the exploration of its chemical properties and potential applications in various fields. Its unique structure and reactivity make it an interesting candidate for the development of new compounds and materials with specific functions and properties.

InChI:InChI=1/C9H9BrO2/c10-6-8-3-1-7(2-4-8)5-9(11)12/h1-4H,5-6H2,(H,11,12)

Upstream product

• 622-47-9 4-tolylacetic acid 
• 94-36-0 dibenzoyl peroxide 
• 34241-39-9 azobisisobutyronitrile 

Downstream Products

• 61165-81-9 p-(acetoxymethyl)phenylacetic acid 
• 66270-97-1 4-(bromomethyl)-phenylacetic acid phenacyl ester 
• 119549-48-3 (4-Bromomethyl-phenyl)-acetic acid 2-trimethylsilanyl-ethyl ester 
• 56066-91-2 4-chloromethylphenylacetic acid 
• 1200-05-1 2-(4-(aminomethyl)phenyl)acetic acid 
• 96044-43-8 4-(2-hydroxyethyl)benzyl bromide 
• 80613-19-0 4-Bromomethylphenylacetic acid (4-methoxy)phenacyl ester 
• 119549-47-2 2-(4-(bromomethyl)phenyl)acetyl chloride 
• 140233-65-4 (4-bromomethylphenyl)acetic acid benzyl ester 
• 223123-57-7 4-(2,2-dicarboethoxypropyl)phenylacetic acid 
• 210834-07-4 2,2,2-trichloroethyl 4-bromomethylphenylacetate 
• 54225-86-4 (3,4-methylenedioxyphenyl) phenyl methanone 
• 7398-42-7 methyl 2-(4-(bromomethyl)phenyl)acetate 

Relevant academic research and scientific papers

Synthesis of α-Helices Having a Positively Charged Random Coil-Block on Either N- or C-Terminal

To study a charge-induced stabilization of α-helix, α-helical peptides having a positively charged random-coil block on either N- or C-terminal of the helix, and having a strictly defined length, (Ala)20(X)20Phe and (X)20(Ala)20Phe(X=Lys or Orn), were syn

Photocatalytic continuous bromination method

The invention provides a photocatalytic continuous bromination method. The method comprises the following steps: carrying out a first-stage photocatalytic continuous bromination reaction on a materialcontaining an aromatic substrate with a structural general formula I and a bromination reagent in a first continuous illumination reactor to form a first continuous system; overflowing the obtained first continuous system into a second continuous illumination reactor for a second-stage photocatalytic continuous bromination reaction to form a second continuous system; and purifying the second continuous system, wherein the structural general formula I is shown in the specification, R is selected from any one of carboxyl, ester group, NO2, CN, C1 to C8 alkyl and alkoxy, and R1 is C1 to C8 alkyl; n is 1 or 2; X is N or C, and the bromination reagent is Nbromo succinimide or dibromohydantoin. According to the bromination reagent, the selectivity of a product is improved, so the yield of the product is improved; the photocatalytic continuous bromination reaction of the two stages effectively relieves the reaction heat accumulation, and enhances the yield of the target product.

Preparation method of netarsudil mesylate

The invention relates to a preparation method of netarsudil mesylate.Netarsudil mesylate is synthesized by utilizing chiral induction, and compared with an existing chiral HPLC method or SFC method, netarsudil mesylate prepared by adopting a chemical synt

Nitroxide derivative of ROCK kinase inhibitor

The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.

BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME

The present invention discloses a biaryl urea RORγt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORγt inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an RORγt-related disease.

p-bromomethyl phenylacetic acid preparation method

The present invention provides a p-bromomethyl phenylacetic acid preparation method, which comprises: dissolving p-methyl phenylacetic acid in a high boiling point solvent, wherein the solvent is benzene, chlorobenzene or dichlorobenzene; adding a bromina

Process for the preparation of kinase inhibitors and intermediates thereof

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

Preparation method of AR-13324

The invention relates to a preparation method of AR-13324. According to the invention, a chiral ligand is used for chiral induced synthesis of AR-13324. In comparison with an existing chiral HPLC method or a SFC method, the method of the invention has the

6-Membered heterocyclic compound and use thereof

A compound represented by the general formula (I) or a salt thereof: [T represents oxygen atom and the like; V represents CH2 and the like; RO1 to RO4 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents ethylene group, trimethylene group and the like; E represents —CH(OH)— group and the like; and W represent —U1—(RW1)(RW2)—U2—U3 group (U1 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; RW1 and RW2 represent hydrogen atom and the like; U2 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; and U3 represent an alkyl group having 1 to 8 carbon atoms and the like), or a residue of a carbon ring or heterocyclic compound], which can be utilized as an active ingredient of medicaments effective for prophylactic and/or therapeutic treatment of skeletal diseases such as osteoporosis and fracture, glaucoma, ulcerative colitis and the like.